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To my Mother Anna-Greta. I wish you were here. 

Abstract 
The overall aim of this work has been to investigate methodological issues connected to 
long-term follow-up of infections diseases. The work extended to prevalent cohorts in 
general. The common denominator for the main methodological efforts in these four papers 
is issues connected to selection bias. In the first three papers methods for visualizing 
selection bias in prevalent cohorts were explored and different approaches to adjust for this 
bias discussed. In the fourth paper, capture-recapture modeling was used to examine 
ascertainment level for liver cancer in the Swedish Cancer Register. 
Study 1: In this study we investigated a novel approach to visualize and adjust for selection 
bias in prevalent cohorts. The method is an extension of the standard interval-based 
approach, where a risk estimate is calculated for disjointed time periods after inclusion in the 
cohort of interest. In the proposed method, observation time and events are cumulated, 
giving more power and more precise estimates which may be useful for studies with few 
events where it may be difficult to judge what is a true effect and what is random noise. The 
proposed method, cumulative SIR, is exemplified using data on hepatitis-C virus infection 
and the outcome liver cancer and non-Hodgkin lymphoma. The results using this novel 
approach were comparable to a standard approach with disjoint intervals. The results 
indicate that the method may be useful in situations with few events in the cohort. The 
method is only useful for cohorts where the risk of the studied outcome is fairly stable over 
time. 
Study 2: Spurious observations have indicated that there may be a relationship between 
hepatitis C virus (HCV) infection and kidney cancer. In this study the relationship between 
HCV-infection and kidney cancer was investigated by use of disease registers. In addition 
the known association of HCV-infection and other forms of kidney disease was explored 
further. Methods for investigating selection bias explored in Paper I were used, in addition 
new ideas were investigated which were further developed in paper III. The relationship 
between HCV-infection and kidney cancer was not confirmed in this study, but the 
association of HCV-infection with other kidney-related diseases was investigated further. 
Study 3: For cohorts that may have high hazard immediately after inclusion in the cohort, 
which then first decreases to later increase with follow-up time, the method of cumulative 
SIR must not be used. The cumulative properties will obscure the initial decrease and the 
method cannot give clear answers. In paper III we used restricted cubic splines to model to 
instantaneous failure rate (hazard). The shape of the hazard function may give an indication 
of the possible presence of selection bias in the cohort. The proposed method was 
exemplified using 1) data on HCV-infection where the outcome of interest was ‘kidney 
disease’ and 2) a cohort a patients with Monoclonal Gammapathy of Uncertain Significance 
(MGUS) and the outcome of interest ‘death’. The model was useful to study the shape of the 
hazard in the cohorts and the number of knots was adjusted to give a suitably flexible model, 
clearly showing the shape of the hazard without being too flexible. 
Study 4: In this study we explored capture-recapture modeling, using a log-linear model to 
estimate ascertainment level of the Swedish Cancer Register (CR). We used a three-source 
model: CR, the National Patient Register (PR) and the Cause of Death Register (DR). Due to 
the limited degrees of freedom in available data, a full model can not be used. We chose to 
estimate a single two-way interaction between the most dependent registers (DR and PR) 
and a three-way interaction. This model will estimate the number of unreported cases of 
liver cancer to about 25% of the total number of cases in all three registers together, 
accounting for overlap. The analysis is likely to be biased by false positive cases 
identified in the PR and/or DR. 
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1. Introduction 
 
The focus of this thesis is selection bias – how and why register based cohort studies 
may be biased because the cohort we study is not be representative of the population 
we are interested in. Usually a cohort or a register contains a subset of the population 
we are interested in, and different selection processes and mechanisms affect which 
population is actually captured by the register. There are almost no exceptions to this 
rule, even the birth register listing all live births in Sweden is thought to miss 0.5-3 % 
of all births (1). Other registers, which are thought to be complete, e.g. the cause of 
death register, may be complete in the sense that all or most deaths are captured, but 
instead the correctness of the recorded underlying causes of death may be questioned. 
The cancer register aims to be complete, and diagnosis of cancer is notifiable by law, 
but completeness may be questioned (2). The same is true for the National Patient 
Register, which is used routinely for all inpatient episodes; meaning that all patients 
who are hospitalised are recorded in this register, but the validity of the recorded 
diagnoses may sometimes be questioned 
 
2. Cohorts for research 
 
 
The methods discussed in the papers for this thesis have utilized epidemiological cohort 
data from a number of registers in Sweden. These registers are described briefly below. 
 
HCV-cohort 
For a number of infectious diseases in Sweden, it is mandatory to report newly 
diagnosed cases, which are recorded in national registers kept by The Public Health 
Agency of Sweden. Hepatitics C virus infection is among those infections that are 
notifiable by law. HCV was detected in 1989 and between the years 1990 and 2006, 
43,000 cases of HCV-infection were reported. Before 1990, HCV was not diagnosed. 
Since HCV-infection often is asymptomatic or mildly symptomatic during long periods 
of time before being recognized,  it is likely that a large number  of individuals with 
HCV are not identified at all and also that diagnosis sometimes occurs late in the course 
of infection. HCV infection has been linked to cancers such as non-Hodgkin 
lymphoma, liver cancer and also kidney diseases (non-cancer) (3-5). 
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MGUS-cohort 
Monoclonal gammopathy of uncertain significance (MGUS) is a condition in which an 
abnormal protein (monoclonal protein or M protein) is increased in the blood. Some 
patients with MGUS may progress to malignant disease and it is likely that mortality is 
elevated in this patient population (6). Since MGUS is a silent asymptomatic condition, 
it is likely to be diagnosed in conjunction with medical problems emerging from 
MGUS or other unrelated medical problems. The studied cohorts, who have been 
gathered in hospital clinics, are therefore not likely to be representative of a true cross-
sectional selection of patients with MGUS. 
 
The Swedish Cancer Register 
The Swedish Cancer Register (CR) was founded in 1958. It is compulsory for every 
health care provider to report newly detected cancer cases to the registry. A report has 
to be sent for every cancer case diagnosed at clinical, morphological or other laboratory 
examinations as well as cases diagnosed at autopsy, i.e. dual reports in most cases. The 
basis for diagnosis is recorded. The CR does not receive information from death 
certificates for the purpose of ascertaining new cases. A quality study of the CR 
estimated the underreporting at approximately 4 percent and found the degree of 
underreporting was dependent on the cancer site, increased with age and diagnoses 
without histology or cytology were overrepresented (2). The liver and pancreas are 
among the cancer sites with a higher degree of underreporting.   
 
The Cause of Death Register 
The Cause of Death Register (DR) includes all deaths among Swedish residents, relies 
on information from death certificates (missing in only 1-2% of deaths). In the DR, the 
date and cause of death (underlying and contributing) and the basis for the diagnosis are 
recorded. 
 
The National Patient Register 
In the 1960's the National Patient Register (PR) started to collect information regarding 
inpatients at public hospitals. From 1984 the participation was mandatory for all county 
councils and from 1987 the PR includes all inpatient care in Sweden. Every inpatient 
episode is recorded with dates and diagnoses at discharge. The validity has been 
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reported to be high for most inpatient diagnoses. Patients who have never been 
inpatients will not be in this register. In this study we did not use the outpatient register. 
 
Diagnoses in these three registers are coded according to the International Statistical 
Classification of Diseases and Related Health Problems (ICD). The cancer diagnoses in 
the Cancer Register are available as ICD-7 codes for the whole study period, 1975–
2011. The diagnoses in the Patient Register and Death Register were classified 
according to ICD-8 in 1968–1986, ICD-9 in 1987–1996, and ICD-10 from 1997 and 
afterwards. 
 
Statistics Sweden 
Statistics Sweden keeps census data for the full population, including migration, 
demographic and economic data. All Swedish citizens have a unique 10-digit personal 
identification number (7). This identification number may be used to uniquely connect 
entries in different register. It may also be used to retrieve general information on 
demographic characteristics and migration from Statistics Sweden. 
 
 
3. Selection bias 
 
Selection bias is a concern in any cohort where the individuals in the cohort are not 
representative of the cohort of interest (8). Figure 1 below describes the relationship 
between a source population and a study population. A) The source population is the 
total population of all individuals with the condition of interest, diagnosed and 
undiagnosed. Nested within the source population is B), the diagnosed cohort: all 
individuals diagnosed and included in the register or cohort. Finally, nested within B) is 
C), the study population which is often smaller than the diagnosed cohort, because for 
example, individuals are excluded to avoid selection bias. The study population is 
seldom a random selection of the source population, which means that the possibility 
for selection bias must be considered (6). 
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Figure 1. An example showing the relationship between source population, diagnosed 
cohort and study population for patients with HCV-infection. 
 
Selection bias is a concern in both incident and prevalent cohorts, but the mechanisms 
may be different and also adjustment for this bias needs to be addressed in different 
ways. In this thesis, only selection bias for prevalent cohorts is discussed. 
 
Prevalent versus incident cohort 
A prevalent cohort may be described as a cohort where individuals are sampled 
according to a cross-sectional sampling criterion (9). This means that the first period of 
the disease is usually unobserved. The length of this unobserved period may differ 
between individuals. In contrast, an incident cohort is a cohort where individuals are 
included at the onset of disease and followed forwards. For some diseases the onset is 
asymptomatic or very mildly symptomatic. These diseases are rarely diagnosed at onset 
but rather at some later time point; either through screening programs or when the 
disease is reaching a symptomatic stage or as complications to the condition arise or as 
a coincidental finding when patients seek medical attention for other, unrelated health 
care problems.  
The possibility for selection bias is obvious when the underlying disease develops 
under long time periods and patients reaching a symptomatic stage of the disease have a 
higher probability of being diagnosed with the disease. When the probability of 
diagnosis of the initial disease, and thereby inclusion in the cohort, is related to the risk 
of the studied outcome, the cohort may be affected by selection bias.  
The term prevalent cohort was used frequently in the early HIV/AIDS era to discuss 
and model scenarios for HIV developing into AIDS (10-12). For the cohorts and 
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conditions studied in this research project; HCV and MGUS, the terms prevalent cohort 
and the theory surrounding prevalent cohorts are equally valid since these conditions 
are rarely diagnosed at the onset of disease. Both MGUS and HCV are asymptomatic 
or mildly symptomatic before eventually turning into a more severe disease (13). 
When the first time period of the disease or infection is unobserved in a prevalent 
cohort, this may lead to additional challenges. Usually, the length of the unobserved 
period of the initial disease varies between individuals and the length of this period is 
usually unknown. Sometimes the length of the unobserved period may be related to 
some specific covariate and if this specific covariate is not taken into account this may 
result in a specific form of bias called onset confounding (10). The first unobserved 
time for individuals in prevalent cohorts is termed backward recurrence time (14). An 
additional challenge is left-truncation, i.e. patients may have experienced the outcome 
of interest, i.e. HCV-infection followed by liver cancer before being included in the 
cohort (15). 
If the length of backward recurrence times are ignored in epidemiological studies, it 
would mean that all individuals are evaluated on the same time scale; follow-up time. If 
the interest is focused on the natural course of disease, ignoring left-censoring and left-
truncation will give non-informative risk estimates. Sometimes covariates, such as 
CD4-count in HIV infection, may give information on the duration of the unobserved 
period of disease. If all information about the length of the unobserved time period 
could be captured by covariates, left-censoring of data would not be important, the 
information would be captured by the covariate. 
Another way to capture information on the length of the unobserved time period of 
disease is to use available epidemiologic information to model the unobserved time 
period (3, 4). For our previous work on HCV-infection and non-Hodgkin lymphoma 
and liver cancer respectively, we constructed a model taking into account development 
of the HCV-infection epidemic in Sweden, age and route of transmission of infection. 
The subsequent analysis may then use this information, either to stratify results by prior 
time of disease or as part of the statistical analysis.  Some statistical methods are better 
suited to handle left-truncated data (14). 
The presented methods to investigate and adjust for selection bias in this thesis may be 
applicable to a wider range of cohorts. In any situation where the method or process for 
gathering (identifying) members of the cohort is positively correlated with the risk for 
the studied outcome, the proposed methods may be applicable. This means that in a 
situation where there is a common cause for both the studied outcome and probability 
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of inclusion in the cohort, there is a possibility for selection bias. However for 
conditions and diseases where the condition confers an immediate risk of the studied 
outcome, like influenza or meningitis, a higher risk of the studied outcome (e.g. death) 
early after inclusion in the cohort may not be described as selection bias and the 
methods discussed here are not applicable. These are incident cohorts and selection bias 
must be handled in other ways. 
 
4. Correcting for selection bias 
 
Selection bias in prevalent cohorts is well known and a method, which is sometimes 
used to adjust for selection bias, is simply to remove some observation time (months 
to years) and any events occurring during this first time period of observation. When 
the cohorts are large with many events, this is a reasonable approach. 
A simple method to investigate selection bias in cohort studies is to calculate effect 
estimates for several disjoint time periods after inclusion in the cohort (16). If the 
planned statistical method for the analysis is Standardized Incidence Ratio (SIR), this 
SIR is calculated for several separate time periods from the start of the observation 
time. This means that one estimate is calculated for the first 6 months the individuals 
(patients) are members of the cohort, another SIR estimate for month 7-12, month 13-
18, month 19-24 etc. If these estimates are higher (not necessarily statistically 
significantly) during some of the earlier time periods compared to later time periods, 
this may indicate selection bias of the type discussed here. The judgment is informal 
and from a statistical point of view, the effect estimates for the time periods are very 
seldom statistically significantly different due to low power. Judgment is based on 
observing the point estimates and using medical knowledge and information on how 
the cohort has been gathered. After removing person years and events occurring 
during these early time periods, the analysis is conducted as planned. 
The increase in the effect estimate during the first few time periods may be due to 
selection bias, but there are also other possibilities. Another explanation may be 
surveillance bias; an observed higher incidence of the studied outcome during the first 
time period after inclusion in the cohort due to increased surveillance for the studied 
outcome. An increased surveillance for the studied outcome may lead to an initial 
higher incidence of the studied outcome and the incidence will then decrease as the 
initial depletion of outcomes takes effect. If the true incidence is increasing with 
follow-up time in the cohort, this could theoretically give a “double peak” in the 
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studied outcome. For the outcomes studied in the two papers on selection bias in this 
thesis, non-Hodgkin lymphoma, liver cancer, death and hospitalisation due to kidney 
related disease, surveillance bias has been assumed to be negligible (17, 18). The 
reason for this is the severity of the studied outcomes, making it very likely these 
outcomes would be diagnosed approximately at the same time, regardless of diagnosis 
of the underlying condition. 
The distinction between selection bias and surveillance bias may be subtle. The 
selection bias described above may also be understood as a surveillance bias if the 
focus is diagnosis of  HCV-infection or MGUS. Patients presenting with medical 
problems, maybe emerging liver problems or symptoms relating to a failing immune 
system, will be subject to further medical examinatons and an HCV-infection or 
MGUS is more likely to be diagnosed for these patients compared to patients who are 
well. If one chooses this perspective, this bias may be described as surveillance bias, 
i.e. increased surveillance for HCV/MGUS. In the projects presented in these papers, 
we choose to view the problem from another perspective, and that is how representative 
the cohort is for the source population. Which terminology is the most appropriate to 
describe a bias not always clear and another expression which is sometimes mixed up 
with selection bias is confounding by indication (19). What matters is to understand the 
mechanism of bias and to be able to describe how this bias arises and to understand 
how this bias may be avoided or adjusted for. 
 
 
5. Selection bias using casual inference and DAG-theory  
 
In discussions of confounding and selection bias, directed acyclic graphs (DAGs) may 
be used to graphically describe and analyse how selection bias enters a cohort study 
(20). Possible mechanisms for selection bias in prevalent cohorts is described in Figure 
2 using DAGs. 
The objective is to study if the asymptomatic or mildly symptomatic disease (X) causes 
the outcome (Y), this is denoted X → Y. The disease X may cause Y either directly or 
by first developing into a more severe symptomatic stage (S) before progressing to Y. 
Only patients diagnosed with the disease (X) can enter a diagnosed cohort (D), which 
forms the basis for the cohort study. Since the disease is asymptomatic or mildly 
asymptomatic, not all patients with disease X are diagnosed. Patients who have entered 
a symptomatic stage of the disease (S) will more easily be identified and diagnosed as 
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having X. This increased probability of diagnosis of patients with symptomatic disease 
will lead to selection bias; that is, patients in the diagnosed cohort D will not be 
representative of the total study base (source population). Patients with a more severe 
stage of disease X, already progressing towards Y, will be over-represented among the 
diagnosed. In the situation described in the directed acyclic graph, we are interested in 
the relation whereby X causes Y  (X→Y), either directly or over the symptomatic stage 
S . Conditioning on D, that is being diagnosed with the condition X, which we must do 
because we may only study patients who have been diagnosed and are part of the 
diagnosed cohort, opens a path from X to Y over the inverted fork D, leading to the 
selection bias described. Quantitative estimates of the risk of Y for patients with the 
disease X, may be biased toward higher estimates because the population in D is not 
representative of the total population with the disease X. Other unknown or 
unmeasured common causes (here, named U) that both cause the outcome Y and lead 
to diagnosis of X  (i.e., D = 1) may introduce further selection bias into the analysis. An 
example of an unknown, unmeasured confounder would be in the MGUS-example 
presented in paper 3, where patients with a severe illness are more readily  diagnosed 
with the condition X (MGUS) and also have and increase risk of dying, which was the 
study objective: to investigate if MGUS patients have increased mortality. Estimates of 
mortality for the MGUS-cohort may therefore be biased towards showing excessively 
high mortality. 
 
 
Figure 2. Description of selection bias using Directed Acyclic Graphs. 
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The processes described here should ideally be viewed as processes over time, 
something that may be quite complicated by using causal inference and directed acyclic 
graph theory. Selection bias caused by diagnosis of patients who have reached a 
symptomatic phase of the disease (S) may be dealt with by excluding patients who very 
soon after diagnosis of X reach the outcome Y. In practice this means that we choose to 
disregard the first time period (and outcomes Y) occurring soon after diagnosis of X. 
This will weaken the path between S and D. When the common cause U leading to the 
outcome Y and diagnosis of X  (i.e. D=1) is an acute illness, the selection bias effect of 
this common cause is likely to be more pronounced just after diagnosis of the acute 
illness. 
Theoretically we could close the backdoor path by either conditioning on S 
(conditioning will close this node) or by not conditioning on D (this will close an 
inverted fork). However, we may only study patients who are actually diagnosed, i.e. 
D=1, and there is no straightforward way to correct for S because it is only possible to 
study individuals that are actually diagnosed. A better approach is to weaken the arrow 
between S and D by removing time and events after diagnosis of X as described above. 
If this arrow is weakened or abolished by removal of observation time and events, the 
backdoor path over S is closed. 
 
6. Capture-recapture models to quantify ascertainment 
level in registers 
 
Introduction 
Capture-recapture modelling was originally known from ecological research to quantify 
wild-life population sizes. The principle is easy and the basic idea is to capture a 
number of animals in a defined area/population, mark these animals in some way, let 
them go, and then make a second capture. Based on the information of the number of 
marked animals in the second capture, it is possible to estimate the total population 
size. This simple model assumes independence between the two sources (captures) of 
animals. In medical epidemiological research the situation is more complex, partly 
because independence between sources cannot be assumed and also because other 
factors beyond statistics may influence the validity of the results to an even greater 
extent. The capture-recapture methods have been extended to handle more complex 
scenarios with dependent sources and covariates. These methods are now used in 
epidemiology to estimate ascertainment level in medical registers (21, 22).  
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For a two-source model as described above, the data that will be available for 
modelling has three degrees of freedom and for this  reason independence between the 
two sources is assumed; there is not enough information to model a possible 
dependence between sources (23). For models using three or more sources, more 
information will be available and it is possible to model dependence between sources.  
In the capture-recapture modelling presented in this thesis (paper IV) we have used the 
following sources (captures); the Swedish Cancer Register (CR), the National Patient 
Register (PR) and the Cause of Death Register (DR) in an attempt to estimate the true 
liver cancer incidence in Sweden and to explore the usefulness of capture-recapture 
models in this setting. These sources are clearly not independent as reporting into the 
various registers are highly dependent processes, e.g. a cancer being diagnosed in the 
hospital during an inpatient episode will increase the probability of this cancer also 
being reported to the CR. Further, a patient with a liver cancer reported to the CR who 
later dies is more likely to be recorded in the DR, with liver cancer either as underlying 
cause of death or contributing cause of death, compared to a patient with an 
undiagnosed liver cancer. 
 
Models for capture-recapture  
The full model 
Capture-recapture modelling may be done in different ways, but a simple 
straightforward approach is log-linear modelling (24). A full (saturated) log-linear 
model for a three source model would be on the following form where the three sources 
are named A, B and C. The model will need coefficients for the three separate sources 
(β), there are also three separate two-way interactions (γ), one three-way interaction (θ) 
and in addition the intercept (α); in total 8 parameters. 
 log𝑁 =   𝛼 +   𝛽! ∙ 𝐴 +   𝛽! ∙ 𝐵 + 𝛽! ∙ 𝐶 + 𝛾! ∙ 𝐴𝐵 + 𝛾! ∙ 𝐵𝐶 + 𝛾! ∙ 𝐴𝐶 + 𝜃 ∙ 𝐴𝐵𝐶 
  
Data from three different registers as described above and the information on which 
cases are registered in two or three of these registers will provide 7 degrees of freedom 
(number in each separate register, number in all combinations of two registers and 
number of cases present in all three registers). This means that a fully saturated model 
is not possible to fit, at least one of the parameters in the model needs to be omitted. In 
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some previous studies, the three-way interaction has been set to zero (22, 25-27). This 
may be a major assumption. When the three-way interaction is set to zero, the intercept 
is simply adjusted to fit with three two-way interactions and a no three-way interaction. 
For our modelling, all two-way interaction terms have negative coefficients since the 
registers in our example are all positively correlated, i.e. the overlap is greater as would 
be expected for independent sources. Therefore, in our modelling, to accommodate 
three negative two-way interactions, the intercept will take a large positive value when 
the three-way interaction is fixed to zero. The number of “missing” cases, i.e. cases 
captured by any of the three registers, is estimated as exp (𝛼), and therefore an inflated 
intercept will give a high number of unreported cases. Also, we have no means of 
evaluating model fit since we cannot check the assumption of a zero three-way 
interaction (28). A log-linear model may also include covariates, which may to some 
extent compensate for dependence between sources (21). 
 
Modelling options 
Since a full model including a three-way interaction is not possible, we explored the 
following modelling options: 
 
A. A two-source model, created by joining the two most dependent sources 
(registers). 
B. A three-source model with three separate two-way interactions and no three-
way interaction. 
C. A three-source model with a single two-way interaction for the two most 
dependent registers (sources) and a three-way interaction. 
 
Model A 
Joining the two most dependent source into one source is a useful approach if two 
sources are heavily dependent and if independence between this joined source and the 
remaining source may be assumed (29). Of the models discussed here, model (A) 
would be expected to be slightly conservative since the process of joining two sources 
and then assuming independence would be expected to underestimate the number of 
unidentified cases. Model A may therefore be considered to provide a lower bound for 
the number of unascertained cases (30). By positive dependence we understand that the 
sources overlap to a greater extent than would be expected from independent sources. If 
we fail to compensate for a ‘net positive dependence’ we risk underestimating the 
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number of undiagnosed cases and also vice versa; if we fail to compensate for ‘net 
negative dependence’ we may overestimate the number of undiagnosed cases (31). 
 
Model B 
In our case, model B turns out to give a very large number of unreported cases, but it is 
not possible to say that a model without a three-way interaction will always over-
estimate the number of unreported cases. In a full log-linear model as described above, 
the three-way interaction doesn’t have an intuitive value or interpretation. Therefore, 
when fitting a model with a three-way interaction set to zero, we have limited means of 
investigating if this assumption is reasonable, it may be difficult to know if it is 
conservative assumption or if we risk overestimating the number of unreported cases. 
As described previously the intercept will be adjusted to account for three separate two-
way interactions, which in the application investigated for our paper will inflate the 
intercept and give a very high number of unascertained cases. 
 
Model C 
Model C, which was the model we chose for our application, involves fitting a two-way 
interaction for the two most dependent sources and a three-way interaction. For the 
studied application of liver cancer, the overlap between the PR and DR was the greatest 
overlap and therefore this interaction term was estimated. The suggested model takes 
into consideration the strongest dependence between two of the sources, while ignoring 
the weaker dependencies. Therefore, all other assumptions being valid, this model 
should also be slightly conservative, i.e. underestimate the number of unreported cases. 
The most important feature of model C compared to model A and model B is that a 
three-way interaction is estimated. Also other models involving a three-way interaction 
are possible to fit. An obvious example would be a model with two separate two-way 
interactions and a three-way interaction (in addition to an intercept and a coefficient for 
each source). Such a model will give a slightly higher estimate of unreported cases 
compared to a model with one two-way interaction. The reason for our preference for 
the simpler model with one two-way interaction is simplicity and the desire to choose a 
slightly conservative model. Most dependencies will be captured by one two-way 
interaction and a three-way interaction. To the non-statistician, the concept of adjusting 
for the two most dependent sources should be straightforward. From a methodological 
perspective we consider this model to be superior to the model with the three-way 
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interaction set to zero since the assumptions we are making may be more readily 
examined. 
 
Capture recapture models – assumptions 
There are a number of underlying assumptions and conditions for capture recapture 
estimates to be valid (32). 
1) Firstly, the cases need to be defined and ascertained in the same way for all 
sources. This is an important condition, which may be violated for 
epidemiological studies employing different sources where it is possible that 
the diagnosis was made in different ways and where bases for diagnosis differ 
between sources. 
2) Within a source, each case needs to have the same probability of being 
diagnosed by that source. However, all sources do not have to capture the 
same number of cases or have the same probability of capturing a case as 
another source. In formal language, the requirement is homogenous 
catchability. 
3) The methods are applicable for closed populations. If individuals move in and 
out of the cohort, they are available to be captured for shorter time periods, 
implying they will have a lower chance of being captured since they are 
available in the cohort for a shorter time period, i.e. a special case of variable 
catchability as described under 2).  
4) For epidemiological applications the time window must not be to short, the 
‘case’ needs time to be available for catching by the different sources (31). 
This fourth criterion aligns with criteria 2) and 3) concerned with variable 
catchability. 
 
Ascertainment of cases 
In a register-based study, identifying cancers from three different registers, it is evident 
that the bases for diagnosis between these sources may differ considerably. Validity of 
data is important in capture-recapture modelling and there should not be misdiagnosed 
cases in any of the sources. Misdiagnosis, false positive and false negative cases, may 
lead to over- or under estimating the number of missing cases (33, 34).  
For the registers studied in paper four there were 13,749 patients with a diagnosis of 
liver cancer in the three registers. Of these 13,749 patients, 6,439 were reported to the 
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CR and 12,475 patients were reported to the PR and/or DR. A large number of patients 
were reported to the PR and/or DR with liver cancer, but not to the cancer register. One 
reason for the large number of patients reported to the PR but not to the CR with liver 
cancer may be the increasing use of non-invasive imaging methods such as CT and MR 
for diagnosis. Doctors may be reluctant to report a liver cancer diagnosis to the CR 
without PAD, or it may simply be forgotten. Another possible explanation may be that 
some of the liver cancer diagnoses reported to the PR were not so certain. It may be that 
liver cancer was the diagnosis available for the PR at that time, but later when more 
information was available, either retrieved from earlier records or complimentary 
investigations, the final cancer diagnosis reported to CR was a different cancer 
diagnosis. 
This hypothesis is supported by the fact that a large proportion of patients with liver 
cancer diagnosis in the PR were reported to the CR, but with other cancer diagnoses, 
either occurring before the current diagnosis of liver cancer in the PR or after. Of the 
7,310 patients with liver cancer reported to the PR and/or DR, which were not reported 
to the CR, 3,925 of these (54 %) were found in the cancer register with some other 
cancer diagnosis, reported to the CR either before the liver cancer diagnosis or after. 
About 1,390 of these patients were reported with ICD-code 199, cancer at unspecified 
site. It is plausible that a proportion of the liver cancers in the PR and/or DR are not 
liver cancer, but metastases to other cancers. Also, some patients who were reported to 
the PR with liver cancer in conjunction with hospitalisation were later reported to the 
CR with other cancer diagnoses. The large proportion of patients reported with liver 
cancers in the PR and some other cancer diagnosis in CR, indicate that this was an 
important source of bias. Since the capture-recapture modelling relies on the overlap 
(and non-overlap) of registers, a large number of liver cancers in the PR and/or DR that 
are not true liver cancers will seriously inflate the estimate of unascertained cases. The 
present results indicate that the assumption of equal criteria for diagnosis/reporting of a 
case may not have been fulfilled. 
 
Variable catchability and closed population 
An underlying assumption for capture-recapture models to be valid is the assumption of 
homogenous catchability (32, 35). In essence this means that all cases (cancers) should 
have equal probability of being captured by each source (register). Each register 
doesn’t have to “catch” an equal number of cases, but each case should have equal 
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probability of being captured by a given source. This condition is obviously violated for 
register-based studies, e.g. all cancers are not fatal, meaning that all cancers cannot be 
captured by the DR. Also, it may be easily shown that patients with liver cancer in the 
PR and/or DR only, differ with regards to demographic characteristics to patients 
reported to the CR, one example being age; patients in the CR were in our study an 
average of 69 years at the time of reporting of liver cancer while patients with liver 
cancer in PR/DR only, were on average 7 years older. In modelling, if we ignore 
variable catchability, this will give a conservative bias, i.e. we will underestimate the 
number of unreported cases (28, 36). Variable catchability may be accounted for, at 
least to some extent, by including covariates in the log-linear modelling. However, in 
register-based research, most of the interesting covariate information, such as disease 
severity, will not be available. In our modelling we have chosen to ignore variable 
catchability. The justification for this is that 1) the bias is conservative (which is more 
acceptable than non-conservative bias), 2) most covariates that would be of interest to 
adjust for catchability are not available and finally; 3) other sources of bias a likely to 
play a larger role. 
 
7. Conclusion 
 
The papers dealing with selection bias are just scratching the surface (17, 18). Selection 
bias related to study populations not being truly representative for the intended cohorts 
is probably part of most epidemiological research projects. Refining methods for 
analysing and presenting data in epidemiological research can never fully compensate 
for systematic errors in the form of bias. Systematic errors may not be analysed away 
using large samples, we need to deal with these sources of errors with more intelligent 
tools. At the start of this research project, the approach for the three methodological 
papers was aimed at statistical approaches and the objective was to explore useful 
methodologies. Working with these projects made it clear that in depth understanding 
of data and how data has been collected is the basis for an adequate analysis. Selection 
bias may never be interpreted by simply looking at curves in graphs. We need to 
understand the characteristics of the population and the unique features of the disease 
and mechanism whereby patients are identified. Therefore, there is no one solution to 
analyse and adjust for selection bias. Probably some of the most useful tools are graphs 
of hazards, DAG and other visual methods, whereby we can understand the 
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mechanisms for how bias may enter the cohort. By understanding we may adjust our 
analyses to compensate for this bias. 
Regarding the capture-recapture modelling for epidemiological research using disease 
registers, there are some papers focused on modelling and comparing models by 
statistical criteria. In our work it became clear that some of the basic conditions for the 
use of these models might not be fulfilled, at least not for the Swedish registers. If we 
cannot be sure that we don’t have large numbers of large false positives in one of the 
registers, adding log-linear modelling to estimate ascertainment level makes little sense. 
Again, understanding data and the basis for collecting and interpreting data is the 
fundament for an intelligent analysis. 
Equally important is to challenge the models and the assumptions we make. For any 
model we chose to use, we should question this model; by considering alternative 
models (which then preferably should give a similar result) and by examining 
assumptions. For the selection bias papers (17, 18) we had the possibility to compare 
different approaches, which gave concordant results. For capture-recapture models we 
may examine the validity of the model by comparing with simpler models providing 
lower bounds for the number of missing cases. Regarding the validity of underlying 
assumptions these assumption may often be clarified by examining data in more detail. 
For the capture-recapture models discussed in the fourth paper, there are reasonable 
solutions for modelling that can handle interactions and covariates. However, for the 
issues related to differences in case ascertainment by different sources (registers) there 
are no clear-cut solutions that can adjust for this. To adequately analyse data we must 
truly understand data. 
Sometimes questions are as important as answers. The methodological papers in this 
thesis probably create more questions than providing answers. However, questions are 
in some way also answers, if we know enough to question processes, such as selection 
of individuals into cohorts, we can interpret results in light of these uncertainties and 
limitations. 
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8. Summary of papers 
 
Paper I 
 
Motivation 
The idea behind the proposed method in the first paper was to improve the “interval 
based method” for investigating selection bias in prevalent cohort studies. The effect 
measure investigated was Standardized Incidence Ratio (SIR). A common method to 
investigate possible selection bias in a cohort is to calculate SIR for several disjoint 
intervals, where follow-up time and events are divided by follow-up time from 
inclusion in the cohort. If the SIR estimates for the first intervals after inclusion are 
significantly higher (also by the non-statistical meaning of the word) these time periods 
with higher effect estimates are discarded from analysis. It is difficult to give guidance 
on what is “higher”, but generally in prevalent cohorts, there is no obvious reason for 
why the risk of the outcome interest would decrease immediately after inclusion in the 
cohort. The observed risk estimates needs to be judged in light of the known 
characteristics of the medical condition. However, often the number of outcomes in 
each disjoint interval is low (unless very common outcomes are studied). This means 
that the precision and power in each interval is poor with regards to judging what is a 
truly elevated effect measure and what is random noise. The idea in the first paper was 
to develop this interval-based method into a cumulative measure that would have better 
power to reveal how long time periods after inclusion in the cohort that should be 
removed to avoid selection bias. The idea was also to visualize more clearly what is the 
impact of removing a certain time period and the events associated with this time 
period. 
 
 
Material 
To illustrate the use of the proposed method we used data derived from the Swedish 
Institute for Infectious Disease Control and the Swedish Cancer register. All individuals 
with a reported HCV-diagnosis during the time period 1990-2006, after exclusion of 
patients with concomitant HBV-infection, were connected by use of the unique 
personal identification number to the Swedish Cancer register. All patients with a 
diagnosis of liver cancer or non-Hodgkin lymphoma were identified. Data from 
Statistics Sweden was used to correct the cohort for death and emigration. Standardized 
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Incidence Rates were calculated using age-, sex- and calendar year specific incidence 
data for the general population from the Cancer Register.  
 
Methods 
The proposed method of cumulative SIR is based on estimating SIR for the cohort 
repeated many times, removing one day at a time. First the SIR is estimated for the full 
cohort, follow-up starting at day of inclusion in the cohort. In the next step SIR is 
estimated starting from day 2, i.e. the first day with “person years” and events 
occurring during this first day is removed. This procedure is repeated by removing one 
additional day (with person years and events) for each reiterated calculation. This 
procedure is repeated a large number of times, e.g. 730 days (2 years) and the resulting 
estimates are plotted in a graph against time since inclusion in the cohort, see Figure 3 
below showing cumulative SIR for liver cancer in a HCV-cohort. If the estimated SIR 
decreases with time since inclusion in the cohort, this may indicate selection bias. In a 
prevalent cohort where time of inclusion in the cohort is not related to an emerging 
outcome, no specific decrease in hazard immediately after inclusion in the cohort 
would be expected.  
Based on the graph, a suitable cut-off is chosen, where the estimated SIR has levelled 
off to a constant level. If the risk of the studied outcome increases considerably with 
time, the method of cumulative SIR may be difficult to use. The reason for this is that 
this method cumulates observation time and events occurring from day (i) and forward. 
If the risk is higher for long follow-up times, this higher incidence will obscure the 
initial decrease in the SIR estimate. This method is therefore only applicable when the 
SIR levels off to some constant value after the selection bias has worn off. 
 
Results 
The proposed method was illustrated using a cohort of patients notified with HCV-
infection. The studied outcomes were liver cancer and Non-Hodgkin lymphoma, one 
frequent cancer (liver cancer) in this patient population of HCV-infected and one not so 
frequent cancer (non-Hodgkin lymphoma) in this cohort.  
 
Liver cancer 
For liver cancers the number of observed cancers is very high and the calculated SIR 
was in the range SIR=33-40 depending on how much observation time (and events) 
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after inclusion in the cohort was removed, Figure 3. The estimated SIR was high 
immediately after inclusion in the cohort and then decreased during the first year down 
to approximately 34. This indicated that at least a year of observation time and events 
after inclusion in the cohort should be removed to correct for selection bias. Since the 
number of observed events was high, removing observation time and events had little 
impact on the precision of the final results, i.e. width of confidence intervals. SIR was 
estimated to around 34 if at least a year was removed. 
 
 
Figure 3. The cumulative standardised incidence ratio for liver cancer for individuals 
notified with hepatitis C virus (HCV). Dashed lines, 95% confidence interval. 
 
 
Non-Hodgkin lymphoma 
Non-Hodgkin lymphoma is a rare cancer in the HCV-cohort, compared to liver cancer, 
and in a previous study investigating if HCV may increase the risk of non-Hodgkin 
lymphoma, the number of cancers was just sufficient to show this relationship with 
statistical significance (3). In this situation it was difficult to motivate removing long 
time periods and many observed events, unless it really could be shown that selection 
bias was a problem. Also from a medical perspective, these cancers occurring very 
soon after HCV-diagnosis are likely to be related to the HCV-infection, but the only 
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reason these patients were diagnosed with HCV-infection, and included in the cohort, 
was that HCV was diagnosed as a consequence of symptoms of the emerging outcome 
(cancer).  For the data of non-Hodgkin lymphoma, SIR was calculated for disjoint 
intervals after inclusion in the cohort showed high SIR immediately after inclusion in 
the cohort, but the SIR varied between intervals, and it was difficult to set an absolute 
cut-off, Figure 4. The cumulative SIR shows that SIR was slightly elevated if no time 
after inclusion in the cohort was removed, but the impact of selection bias was small if 
3-6 months of observation time and events were removed, Figure 5. 
 
 
 
 
Figure 4. The standardized incidence ratio for non-Hodgkin lymphoma for individuals 
notified with hepatitis C virus (HCV). Interval based method, in which the standardised 
incidence ratio is calculated separately for different time intervals after diagnosis of 
HCV. Dashed lines, 95% confidence intervals. 
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Figure 5. The cumulative standardised incidence ratio for non-Hodgkin lymphoma for 
individuals notified with hepatitis C virus (HCV). Dashed lines, 95% confidence 
interval. 
 
Conclusion 
The examples of HCV-infection and liver cancer and lymphoma show that the 
cumulative method works and that for some scenarios it may have advantages over a 
standard approach; calculating SIR for disjoint intervals. This is especially true if the 
number of events are few and it is therefore important not to discard observation time 
and events unnecessarily.  
The impact of removing a specific time period and events belonging to this time period 
may be read directly from the graph. 
However, the proposed method of cumulative SIR has several important limitations. 
Firstly, this concept of selection bias as it is discussed here is only relevant for 
prevalent cohorts, i.e. when inclusion of the patient in the cohort is not directly 
connected to the time point when the patient contracts the infection of the disease 
which is the denominator for the cohort. HCV-registers are good examples of prevalent 
cohorts. The infection may be symptomatic at infection and the patient may carry the 
infection for years or decades before finally being diagnosed, either in conjunction with 
random screening, because of other medical problems or because the patient is 
presenting with an emerging outcome of the infection, i.e. liver cancer. For incident 
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cohorts, e.g. the study of influenza and mortality, decreasing hazard after inclusion in 
the cohort may have other more likely interpretations such as declining risk of death 
with time. 
Another important limitation of the method is that use of the method assumes that the 
hazard is high immediately after inclusion in the cohort (selection bias) and then 
declines to a steady state level, or at least that the hazard is increasing very slowly with 
time. If the hazard increases steeply with follow-up, the graphing will not work, as 
increasing hazard with follow-up will affect the early parts of the graph, because data is 
cumulated. It is therefore important to map out how the overall hazard for the outcome 
of interest appears in the cohort before applying the proposed method. 
 
Paper II 
 
Motivation 
Chronic hepatitis C virus (HCV) infection is an established cause of liver cancer, and 
studies have also suggested a link with kidney cancer (4). HCV-infection has also been 
shown to increase the risk of other kidney related diseases and this association was 
further explored in this paper. 
 
Material 
The Swedish nationwide register of HCV-infected individuals during the years 1990-
2006 compromising 43,000 individuals was connected to the Swedish Cancer Register 
to identify patient with kidney cancer diagnoses (ICD7 180.0 and 180.9). Data on 
hospitalisation discharge diagnoses were extracted from the National Patient Register, 
using the following ICD-codes:  
1) Glomerular diseases (ICD-9 codes 580–583, ICD-10 codes N00-N08)  
2) Renal failure (ICD-9 codes 584–586, ICD-10 codes N17-N19 
3) Other kidney diseases (ICD-9 codes 587–589 and 593, ICD-10 codes N25-N28).  
Events were defined as the first hospitalisation per subject for which each of the listed 
conditions above were registered as the principal diagnosis code. 
Statistics Sweden provided information on death and date of emigration (if applicable). 
 
Methods 
The Standardized Incidence Ratio (SIR) was calculated using the HCV-cohort linked 
with the Cancer Register and the data on the incidence of kidney cancer in the general 
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population. Indirect standardization was performed with regards to calendar year, age 
(5-year intervals) and sex. To investigate and adjust for selection bias, the cumulative 
SIR method was used and SIRs were calculated with varying lag times (no lag-time up 
to two years) (18).  
For the Cox-regression, a control cohort matched for age, sex and county of residence 
at time of HCV-infection was used. For each HCV-infected individual, five controls 
were selected.  
To avoid selection bias, subjects were excluded from these analyses if they had ever 
been hospitalised with kidney disease as the principal diagnosis from 1969 until one 
year after HCV-notification or the corresponding reference dates for non-HCV-infected 
subjects.  
Subjects who were hospitalised for any condition in the year prior to HCV-notification 
were also excluded, leaving 25,412 HCV-infected subjects and 198,124 controls in 
these analyses. 
Restricted cubic splines were fitted to investigate the change in hazard over time in the 
cohort. These analyses revealed a fairly sharp decrease in hazard over the first year and 
then a slowly decreasing hazard from one year onwards (37). This slowly decreasing 
hazard was judged to reflect frailty in a population consisting of patients with different 
underlying intensity for hospitalisation for kidney-related disease. Conducting an 
analysis based on time to first event will gradually attenuate the population with 
regards to patients with high propensity for hospitalisation, and the hazard will 
therefore decrease slowly with time.  To further control for selection bias, related to the 
sharp decrease in hazard during the first year, follow-up started one year after 
notification of HCV-diagnosis, Figure 6, paper III. 
 
Results 
The calculated SIR for kidney cancer in the HCV-cohort was 1.2 (95% CI: 0.8-1.7) 
using a one year lag-time. Therefore the results of this study do not indicate a 
relationship between HCV-infection and kidney cancer. Chronic HCV-infection was 
associated with a significantly increased risk of hospitalisation for other non-cancer 
kidney diseases. Risk of all non-cancer kidney diseases differed significantly by sex  
(Pinteraction = 0.045). Hazard ratios of 3.9 (95% CI 3.2–4.8) and 5.8 (95% CI 4.2–7.9) 
were observed among men and women, respectively. Among men, risk estimates 
ranged from 2.9 (95% CI 2.0–4.3) for glomerular diseases to 4.6 (95% CI 3.7–5.8) for 
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renal failure. Among women, risk estimates ranged from 5.1 (95% CI 3.0–8.8) for 
glomerular diseases to 10 (95% CI 2.7–37) for other non-cancer kidney diseases. The 
interaction is likely to reflect a lower absolute risk level in women and a poor fit of a 
multiplicative model for both sexes.  
Treatment of end-stage renal disease may involve blood transfusions and 
haemodialysis, which are potential risk factors for HCV-transmission. Reverse 
causation bias was therefore a potential concern in the analyses of hospitalisations for 
non-cancer kidney diseases. However, the impact of this type of bias on the reported 
results is likely minimal because all individuals with prior diagnoses of kidney diseases 
since 1969 were excluded from these analyses. Also, risk estimates were similar after 
excluding subjects for whom transfusion of blood/blood products or nosocomial 
infection was the suspected route of HCV-transmission. 
 
Conclusion 
The present study did not confirm that HCV-infection increases the risk of kidney 
cancer. The known relationship of HCV-infection and other kidney diseases such as 
renal failure and glomerular disease was further confirmed and described in this study. 
 
Paper III 
 
Motivation 
The objective of the method presented in the second paper was similar to that of the 
first paper; to explore methods for visualizing, and thereby providing an opportunity 
to correct for selection bias in prevalent cohorts.  
The proposed method is based on modelling the instantaneous failure rate using a 
restricted cubic spline model. The basic idea is to investigate how and if the hazard 
for the outcome of interest changes as a function of time since inclusion in the study. 
Theoretically, in a cohort where date of inclusion in the cohort is unrelated to any 
emerging symptoms of the outcome studied, no specific change of hazard in relation 
to time of inclusion in the cohort would be expected.  However, if the hazard 
decreases immediately after inclusion in the cohort, to later stabilize or increase 
again, this may indicate selection bias.  
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Material 
The proposed method was applied on two data sets used for previous studies.  
 
1. The HCV-cohort linked to the Swedish Cancer Register described in the 
second paper, studying the association of HCV-infection with hospitalisation 
for kidney related disease (5).  
2. Data from a study examining the excess mortality for patients with MGUS, 
monoclonal gammapathy of uncertain significance (6). 
 
Methods 
The hazard for the cohort is modelled as a function of time since inclusion in the 
cohort. In practice any method for modelling the hazard may be used, as long as the 
model is flexible and the estimates are fairly smooth. The particular advantages of the 
suggested restricted cubic spline model are however several. 
The model is flexible, but not too flexible, where the number of knots (connecting the 
cubic polynomials) may be varied from a few knots up to 10 knots to give a sufficiently 
flexible model. If the model is extremely flexible it may be difficult to discern what is 
true change in hazard and what is random noise. If the model is not flexible enough, the 
model may be too rigid to model the hazard adequately. Since the model allows for a 
range of number of knots, flexibility may be varied to verify that different models give 
approximately the same result with regards to follow-up time that may be affected by 
selection bias.  
The calculations are easy to perform, using just a few lines of code and the package 
stmp2 in STATA. The resulting graphs are easily interpretable and may give additional 
information on e.g. how the hazard for the studied outcome develops over time (37). 
 
Results 
The examples shown; MGUS and HCV with the studied outcomes death and 
hospitalisation due to kidney related disease, respectively, show that this method works 
in practice to identify a time period after inclusion in the cohort possibly affected by 
selection bias. 
For HCV-infection and kidney related disease, the hazard was very high immediately 
after inclusion in the cohort and decreases steeply up to a year after inclusion in the 
cohort. The hazard continued to decrease also after about one year, but very slowly. 
  26 
The first steep phase was interpreted as selection bias – there was no other obvious 
cause for the hazard to decrease immediately after inclusion in the cohort for a 
prevalent condition. The second phase with very slowly decreasing hazard was 
interpreted as frailty as discussed for the second paper above. This may also explain 
why the risk of the studied outcome did not increase with time, Figure 6. 
 
 
 
Figure 6. The hazard for the outcome “first hospitalisation for kidney-related disease” 
was modelled by using a restricted cubic spline model for survival data. The timescale 
on the x axis is time since hepatitis C virus (HCV) diagnosis in years. The solid line 
denotes the hazard for the HCV-cohort modelled with 3 knots; the dotted line, 5 knots; 
and the dashed line, the hazard for the matched control cohort (3 knots). 
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Figure 7. The hazard for the outcome death was modelled by using a restricted cubic 
spline model for survival data. The timescale on the x axis is time since diagnosis of 
monoclonal gammopathy of uncertain significance (MGUS) in years. The solid line 
denotes a model with 2 knots for the baseline hazard; the small dotted line, 5 knots; and 
the dashed line, 7 knots. 
 
 
For MGUS, which is basically an asymptomatic disease in early stages, there was a 
steep decrease in hazard during the first two years after inclusion in the cohort and then 
the hazard started to increase with time, indicating that the hazard (risk) of dying for 
MGUS-patients was increasing with time, Figure 7. 
 
Conclusion 
As for the method cumulative SIR, the method proposed in this paper is not applicable 
for the study of acute diseases where the risk of the studied outcome would be expected 
to be highest immediately after contraction of the disease. In this case a decreasing 
hazard for the outcome studied, immediately after inclusion in the cohort is likely to 
have other explanations. The method is suited for prevalent cohorts where the patients 
are identified as members of cohort at different time points after contraction of the 
initial disease. 
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The method using restricted cubic splines to model hazard has several advantages over 
the method proposed in the first paper. The method of cumulative SIR assumes that the 
hazard reaches a steady state level to which the estimated SIR may level off towards, 
otherwise the early estimations of selection bias are influence by later higher SIR. 
Another advantage of the restricted cubic spline model is that it gives a good view over 
the hazard for the event of interest in the cohort over time, which may provide 
additional information on how the risk of the studied outcome changes over time in the 
cohort. 
 
Paper IV 
 
Motivation 
The aim of this project was to investigate the completeness of the Swedish Cancer 
Register (CR) for hepatocellular carcinoma (HCC) diagnoses and to investigate if the 
low and declining incidence of HCC in Sweden represents a true decrease, or may be 
a result of changed diagnostic procedures. Another objective was to produce a more 
accurate estimate of the true incidence of primary liver cancer in Sweden by 
combining information from the CR, the Cause of Death Register (DR) and the 
Patient Register (PR). A secondary objective of the study was to investigate whether 
a capture-recapture model can be used to reliably estimate the number of cancers not 
reported to any of the registers.  
 
Material 
For the descriptive graphs of liver cancer over time, cancer incidence data was derived 
from the CR for the years 1970-2011. In addition, all individual patients with a cancer 
diagnosis 1550 (primary liver cancer) or 156 (liver cancer, unspecified) in the CR were 
extracted for the years 1975-2011. From the Cause of Death Register, for 1997-2012, 
patients with code C22.0, C22.9 and C22.99 (depending on year), either as underlying 
cause of death or as contributing cause of death, were extracted. The same codes were 
used for extraction from the PR. For the capture-recapture modelling and estimation of 
the true incidence of liver cancer, data from 1997-2012 was used. 
 
Methods 
Liver cancer incidence over the time period 1970-2011 derived from the cancer register 
was presented descriptively, as were the bases for liver cancer diagnoses during the 
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same time period. The number of patients with liver cancer in the CR, the DR and the 
PR were graphed in proportional Venn diagrams showing the number of patients in 
each register separately and also the number of patients present in more than one of the 
registers. The Venn diagrams were fitted so that areas were proportional to the number 
of patients, as closely as possible. For comparison, Venn diagrams for colon cancer and 
lymphoma were graphed and presented, Figure 8. 
 
For the time period 1997 – 2011 data from the CR, DR and the PR was used to model 
the number of liver cancers not reported at all. A log-linear capture recapture model 
was used to estimate the number of liver cancers not reported at all based on the 
number of patients in the CR, PR and DR. A saturated model would need 8 degrees of 
freedom, however, available data has only 7 degrees of freedom so a full model with 
coefficients for each source, all two-way interactions and a three-way interaction is not 
possible to fit. Different models were explored and the model chosen was a model with 
a parameter for each source, one two-way interaction used for one of the possible two-
way interactions and a three-way interaction. Different options for the two-way 
interaction were considered but naturally the model with the two-way interaction for 
the two most overlapping registers was be most appropriate and yielded the lowest 
Akaike value. 
To investigate a lower bound for the number of unreported cases, a two-source model 
was constructed by joining the two most dependent sources (registers), the PR and the 
DR. For a two-source model, independence between these sources must be assumed. A 
two-source-model assuming independence should underestimate the number of 
unreported cases, all other assumptions being correct. Also, a three-source model with 
three different two-way interactions and no three-way interaction was also explored 
since this is an option other researchers have chosen. 
 
Results 
The number of liver cancers in the CR has decreased steadily over since 1970. In the 
same time period, the bases for diagnosis have changed. The proportion of patients with 
a diagnosis based on non-invasive imaging techniques has increased during the later 
years, but biopsy confirmed diagnosis is the most common basis for diagnosis in recent 
time. 
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The graphing using Venn-diagrams showed a large overlap between the registers, 
which would be expected since reporting to different registers is a highly dependent 
process, Figure 8 (38). 
For liver cancer the overlap was largest between the PR and the DR. Noticeably, there 
were a large number of patients reported with liver cancer to the PR, who were not 
reported to the CR. For other cancer investigated, colon cancer and lymphoma, a 
different pattern emerged, with much stronger dependence (overlap) between the PR 
and the CR. This was judged to reflect the different reporting processes where 
diagnosis of liver cancer in an inpatient setting may be set based on non-invasive 
imaging techniques while diagnosis of colon cancer and lymphoma commonly is based 
on histologic confirmation. For these cancers, the diagnosing laboratory, as well as the 
clinic, sends reports to the CR. 
 
Figure 8. Venn diagrams showing number of reported cancers to different registers and 
combination of registers. Areas adjusted to fit number of cases as closely as possible. 
 
The index year was defined as the first year a patient appeared in any of the three 
registers. The total number of liver cancers in all three registers with index year 2008-
2010 was 13,749.  
When studying the patients with liver cancer diagnoses from the DR and PR, not 
reported to the CR, it was found that as many as 3,925 (54%) of these 7,310 patients 
were reported to the CR for other cancer diagnoses. Of these, 1,390 patients were 
reported with ICD-code 199, i.e. malignant neoplasm without specification of site. This 
may indicate that at least part of the liver cancers identified only in PR and/or DR, were 
liver metastases related to other cancers. Making the drastic assumption that all 3,925 
patients registered in the cancer register for other cancer diagnoses had received their 
liver cancer diagnosis erroneously in the PR and DR, this will bring down the total 
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number of liver cancers to 9,824 for the time period 1998-2010. Also, the completeness 
of the CR would then be estimated to 66%, assuming that all liver cancers were 
captured by at least one of the registers, i.e. not accounting for unreported cancers. 
 
Sensitivity analysis 
 
The two-source model gave an estimated number of liver cancers not reported to any 
register corresponding to about 13% of the total number of liver cancers in the three 
registers together, the corresponding figure for the three-source model with a single 
two-way interaction was about 25%.  The three-source model, not accounting for a 
three-way interaction gave very high estimates of the number of unreported cases.  
 
Conclusion 
The CR is likely to underestimate the true incidence of liver cancer in Sweden. A large 
number of cases were reported to the PR and/or DR only. The reason for this may be 
the recommended use of non-invasive diagnostic methods based on imaging 
technologies for liver cancer diagnosis, resulting in a clinical diagnosis which is not 
always reported to the CR. 
The large number of patients with liver cancer reported in the PR and/or DR raises 
concern. It is likely that at least some of these reported cancers are other cancers and 
not liver cancers. When using the capture-recapture model, although mathematically 
correct, the results must therefore be interpreted cautiously.  In spite of these concerns, 
it is likely that the incidence of liver cancer is underreported in the Swedish CR. 
The Venn-diagrams for liver cancer compared to the Venn-diagrams for colon cancer 
and lymphoma indicate differences in reporting routines. The diagnoses of colon cancer 
and lymphoma are usually given on the basis of laboratory histologic confirmation. For 
these cancers the CR appears to be much more complete with about 80% of all cancers 
reported to the CR. 
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